

Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

Journal of Critical Care

journal homepage: [www.journals.elsevier.com/journal-of-critical-care](http://www.journals.elsevier.com/journal-of-critical-care)

## Brain death determination in patients with veno-arterial extracorporeal membrane oxygenation: A systematic study to address the Harlequin syndrome

Farid Salih<sup>a,\*</sup>, Johann Lambeck<sup>b,1</sup>, Albrecht Günther<sup>c,1</sup>, Caroline Ferse<sup>d</sup>, Olaf Hoffmann<sup>e,f</sup>, Konstantinos Dimitriadis<sup>g</sup>, Andre Finn<sup>d</sup>, Stephan A. Brandt<sup>a</sup>, Benjamin Hotter<sup>a</sup>, Florian Masuhr<sup>h</sup>, Stephan Schreiber<sup>i</sup>, Florian Weissinger<sup>j</sup>, Andrea Rocco<sup>k</sup>, Hauke Schneider<sup>l</sup>, Wolf-Dirk Niesen<sup>b</sup>, on behalf of the IGNITE study group<sup>2</sup>

<sup>a</sup> Dept. of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 13353 Berlin, Germany

<sup>b</sup> Dept. of Neurology and Clinical Neurophysiology, University Medical Center Freiburg, Breisacher Straße 64, 79106 Freiburg, Germany

<sup>c</sup> Dept. of Neurology, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany.

<sup>d</sup> Dept. of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany

<sup>e</sup> Dept. of Neurology, St. Josefs-Krankenhaus, Allee nach Sanssouci 7, 14471 Potsdam, Germany

<sup>f</sup> Medizinische Hochschule Brandenburg Theodor Fontane, Fehrbelliner Straße 38, 16816 Neuruppin, Germany

<sup>g</sup> Dept. of Neurology, University Hospital LMU Munich, Marchioninistraße 15, 81377 Munich, Germany

<sup>h</sup> Dept. of Neurology, Bundeswehrkrankenhaus Berlin, Scharnhorststraße 13, 10115 Berlin, Germany

<sup>i</sup> Dept. of Neurology, Asklepios Fachklinikum, Anton-Saefkow-Allee 2, 14772, Brandenburg, Germany

<sup>j</sup> Dept. of Neurology, Vivantes Humboldt-Klinikum, Am Nordgraben 2, 13509 Berlin, Germany

<sup>k</sup> Dept. of Neurology, Klinikum Ernst von Bergmann, Charottenstraße 72, 14467 Potsdam, Germany

<sup>l</sup> Dept. of Neurology, University Hospital Augsburg, Stenglinstr. 2, 86156 Augsburg, Germany

### ARTICLE INFO

#### Keywords:

Brain death  
Harlequin syndrome  
Apnea testing  
Arterial blood gas  
ECMO

### ABSTRACT

**Purpose:** The Harlequin syndrome may occur in patients treated with venoarterial extracorporeal membrane oxygenation (VA-ECMO), in whom blood from the left ventricle and the ECMO system supply different parts of the body with different  $p_a\text{CO}_2$ -levels. The purpose of this study was to compare two variants of  $p_a\text{CO}_2$ -analysis to account for the Harlequin syndrome during apnea testing (AT) in brain death (BD) determination.

**Materials and methods:** Twenty-seven patients (median age 48 years, 26–76 years; male  $n = 19$ ) with VA-ECMO treatment were included who underwent BD determination. In variant 1, simultaneous arterial blood gas (ABG) samples were drawn from the right and the left radial artery. In variant 2, simultaneous ABG samples were drawn from the right radial artery and the postoxygenator ECMO circuit. Differences in  $p_a\text{CO}_2$ -levels were analysed for both variants.

**Results:** At the start of AT, median  $p_a\text{CO}_2$ -difference between right and left radial artery (variant 1) was 0.90 mmHg (95%-confidence intervall [CI]: 0.7–1.3 mmHg). Median  $p_a\text{CO}_2$ -difference between right radial artery and postoxygenator ECMO circuit (variant 2) was 3.3 mmHg (95%-CI: 1.5–6.0 mmHg) and thereby significantly higher compared to variant 1 ( $p = 0.001$ ). At the end of AT,  $p_a\text{CO}_2$ -difference according to variant 1 remained unchanged with 1.1 mmHg (95%-CI: 0.9–1.8 mmHg). In contrast,  $p_a\text{CO}_2$ -difference according to variant 2 increased to 9.9 mmHg (95%-CI: 3.5–19.2 mmHg;  $p = 0.002$ ).

**Conclusions:** Simultaneous  $p_a\text{CO}_2$ -analysis from right and left distal arterial lines is the method of choice to reduce the risk of adverse effects (e.g. severe respiratory acidosis) while performing AT in VA-ECMO patients during BD determination.

\* Corresponding author at: Dept. of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.  
E-mail address: [farid.salih@charite.de](mailto:farid.salih@charite.de) (F. Salih).

<sup>1</sup> Equal contribution.

<sup>2</sup> The Authors have no conflicts of interest (financial and non-financial).

<https://doi.org/10.1016/j.jcrc.2024.154545>


Available online 22 February 2024

0883-9441/© 2024 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Extra-corporeal life support (ECLS) has become an integral part of modern intensive medicine [1-3]. The widespread application of ECLS in recent years has also entailed new challenges for brain death (BD) determination [4-7]. This is most relevant for patients on veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) [8-10]. VA-ECMO is a type of ECLS, which provides temporary mechanical circulatory support and extracorporeal gas exchange and has emerged as a salvage intervention in patients with cardiogenic shock and cardiac arrest refractory to standard therapies [11]. Within the last decade, the number of VA-ECMO treatments has increased markedly [12,13]. At the same time, the hospital mortality of patients treated with VA-ECMO has remained high with up to 66% [12]. Consistent with the underlying diagnoses, there is a relevant risk of BD among VA-ECMO patients, and the number of patients receiving BD diagnostics may continue to rise [4,14,15]. Therefore, it is essential to provide sound evidence for those diagnostic procedures within BD protocols that necessitate special regulations in VA-ECMO patients.

To determine BD, demonstration of absent spontaneous breathing by apnea testing (AT) is mandatory [16,17]. Performing AT during VA-ECMO requires special consideration of its effects on the distribution of blood flow and ABG tensions, depending of the site of ECMO cannulation and the extent of intrinsic cardiac function [8,9]. The Harlequin syndrome may occur in VA-ECMO-patients when left ventricular function starts to recover. Antegrade blood flow from the left ventricle may then collide with retrograde aortic perfusion delivered by the ECMO system, creating a “mixing cloud” [18,19]. If this “mixing cloud” is located in the aortic arch, the right arm and the right side of the head receive blood with higher  $p_a\text{CO}_2$  and lower  $p_a\text{O}_2$  from the left ventricle via the brachiocephalic trunk (Fig. 1). Meanwhile, the ECMO system supplies fully oxygenated and decarboxylated blood to the left arm and the left side of the head via the subclavian and common carotid arteries. In patients with maintained cerebral perfusion, this differential perfusion also affects the chemoreceptors of the medulla oblongata, which is supplied by the right and left vertebral arteries. To address the Harlequin syndrome, several guidelines have introduced recommendations on how to assess different  $p_a\text{CO}_2$ -levels in the right and left side of the body.



**Fig. 1.** Anatomical illustration of the Harlequin syndrome in the aortic arch. Arrows indicate intrinsic blood flow from the left ventricle (purple) and retrograde aortic perfusion delivered by the ECMO system (red), which collide in the aortic arch creating a “mixing cloud”. Consequently, the right arm and the right side of the head receive blood with higher  $p_a\text{CO}_2$  and lower  $p_a\text{O}_2$  from the left ventricle via the brachiocephalic trunk. Meanwhile, the ECMO system supplies fully oxygenated and decarboxylated blood to the left arm and the left side of the head via the subclavian and common carotid arteries. In patients with maintained cerebral perfusion, this differential perfusion also affects the chemoreceptors of the medulla oblongata, which is supplied by the right and left vertebral arteries. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

The main principle is to guide the AT by bilaterally simultaneous ABG analyses, which are drawn either from a right and left distal arterial line (variant 1) or from a right arterial line and the postoxygenerator ECMO circuit (variant 2) [6,8,9,16,17,20]. To date, these recommendations are mainly based on pathophysiological considerations, while systematic validation is largely missing [8,21].

Here we report results of a comprehensive study testing the feasibility of simultaneous ABG analysis to guide AT. Moreover, we systematically compared ABG results from right and left distal arterial lines (variant 1) and ABG results from right arterial line and postoxygenerator ECMO circuit (variant 2).

## 2. Materials and methods

The study was performed in five German university hospitals between 2020 and 2023. We retrospectively analysed patients who underwent BD determination while circulation was sustained by VA-ECMO. The clinical signs of BD (coma, loss of brain stem reflexes, central apnea) were ascertained by two physicians with extensive experience in the care of patients with severe brain injury. At least one investigator was a neurologist. AT was performed with the assistance of a critical care specialist trained in ECLS.

### 2.1. Apnoea testing

Before performing AT, arterial lines were placed as necessary to allow for simultaneous sampling from both radial arteries. At least five minutes of preoxygenation were provided by elevating the oxygen fraction of the mechanical ventilator and of the ECMO system to 100%. VA-ECMO flow rate and/or vasopressors were adjusted to maintain a mean arterial blood pressure of least 60 mmHg. Before AT was started, simultaneous ABG analyses were drawn from the right and left arterial lines (variant 1) or from the right arterial line and the postoxygenerator ECMO circuit (variant 2). Ventilation and ECMO parameters were adjusted as necessary until  $p_a\text{CO}_2$ -levels between 35 and 45 mmHg were present in both samples. AT was then started by either (i) disconnecting the mechanical ventilator and providing intratracheal oxygen insufflation, (ii) setting the mechanical ventilator to continuous positive airway pressure mode with provision of 100% oxygen, or (iii) by providing 100% oxygen via a resuscitation bag with a positive end-expiratory pressure valve. The sweep gas flow rate of the ECMO system was then reduced to 0.5–1.0 L/min to increase  $p_a\text{CO}_2$ -levels. While assessing for spontaneous breathing,  $p_a\text{CO}_2$  was monitored by repeated simultaneous ABG measures until  $p_a\text{CO}_2$  increased to at least 60 mmHg in ABG samples from all sites. After completion of the AT, mechanical ventilation and ECMO were returned to their previous settings. BD was confirmed by an ancillary test.

### 2.2. Statistical analysis

The differences of individual  $p_a\text{CO}_2$ -levels between right and left arterial line (variant 1) and right arterial line and postoxygenerator ECMO circuit (variant 2) were averaged across patients for the time AT was started and for the time AT was completed. Results are reported as median with 95%-confidence intervals (95%-CI) and ranges, or median with interquartile range (IQR) where appropriate. Mann–Whitney-*U* test was used to test for significant differences between variants 1 and 2 (with a significance level of 0.05), using IBM SPSS Statistics 29.0.1.0.

The study was approved by the institutional ethics review board (*Ethikkommission des Universitätsklinikums Freiburg, Germany, IRB-Nr. 22-1140*). Informed consent was waived due to the retrospective nature of the data analysis. All procedures in this study were followed in accordance with the ethical standards of the 1964 Declaration of Helsinki.

### 3. Results

During the study period, 1.8% of all patients treated with VA-ECMO were introduced for BD determination. Twenty-seven patients (i.e., 1.4% of all VA-ECMO patients) received simultaneous  $p_aCO_2$ -analysis according to variant 1 or 2 during AT and consequently fulfilled the inclusion criteria of our study (median age 48 years, 26–76 years; male  $n = 19$ ). All 27 patients were admitted due to cardiogenic shock or cardio-pulmonary resuscitation (CPR) requiring VA-ECMO. ECMO cannulation was performed via femoral arteries and veins in all patients, most often on the right side ( $n = 22$ ; 81,5%). In five patients, VA-ECMO alone was not sufficient to stabilize hemodynamic parameters and additional percutaneous microaxial pumps (Impella® heart devices) were implanted to support ventricular function. The mean interval between admission and BD determination was 3.1 days (range 0–7 days). In the majority of patients (85.2%;  $n = 23$ ) secondary brain injury (hypoxic encephalopathy) due to the initial cardiac or pulmonary emergency was the leading cause of BD. In three patients, intracerebral hemorrhage and subarachnoid hemorrhage (SAH) developed as complications of VA-ECMO implantation and led to BD. In the remaining patient, a primary SAH (grade V° according to World Federation of Neurological Surgeons [22]) led to neurogenic stunned myocardium and later BD. Table 1 summarizes demographic data, diagnosis, ECMO flow-rate, left ventricular ejection fraction, ancillary tests and the aetiologies leading to cardiogenic shock or CPR.

In 25 out of 27 patients, arterial lines were implanted in the right and left radial artery (variant 1). In five out of these 25 patients, simultaneous ABG samples were taken from both distal arterial lines and also from the postoxygenator ECMO circuit (combination of variants 1 and 2). In the two remaining patients, implantation of lines in the left distal arteries (radial or brachial artery) was not possible and ABG samples were taken simultaneously from right radial artery and postoxygenator ECMO circuit. Consequently, 25 data sets were analysed for variant 1 and seven data sets for variant 2.

In all patients ( $n = 27$ ), simultaneous ABG analysis according to variant 1 or 2 or both was feasible to guide AT. There were no instances where AT had to be stopped due to cardiac, hemodynamic or respiratory instability and in no patient exogene  $CO_2$  had to be supplied via the ECMO system to support hypercapnea. No negative results in AT were encountered, no patient started breathing during AT. BD was ultimately determined in all participants.

#### 3.1. Simultaneous ABG analysis at the start of AT

At the start of AT, median  $p_aCO_2$  of the right radial artery across all patients ( $n = 27$ ) was 40.2 mmHg (IQR 37.1–42.1 mmHg, range 34.4–44.0 mmHg). With regard to variant 1 ( $n = 25$ ), median baseline  $p_aCO_2$  levels of right and left radial arteries were 40.3 mmHg and 39.5 mmHg (95%-CI: 38.9–41.1 and 38.6–40.9 mmHg;  $p = 0.75$ ). Fig. 2 illustrates the initial distribution of individual  $p_aCO_2$ -differences according variant 1 and 2. The median difference at baseline between right and left radial  $p_aCO_2$  was 0.90 mmHg (95%-CI: 0.7–1.3 mmHg, range 0.0–2.7 mmHg; Fig. 3). In variant 2 ( $n = 7$ ), baseline  $p_aCO_2$ -levels in the right radial artery and in the postoxygenator ECMO circuit were 39.2 and 38.5 mmHg (95%-CI: 36.1–42.4 and 34.0–40.4 mmHg;  $p = 0.40$ ). The median  $p_aCO_2$ -difference between right radial artery and post-oxygenator ECMO circuit was 3.3 mmHg (95%-CI: 1.5–6.0 mmHg, range 0.7–7.5 mmHg; Fig. 3), significantly higher than in variant 1 ( $p = 0.001$ ). With variant 1, higher baseline  $p_aCO_2$ -levels were found on the right side in 13 out of 25 patients, 11 patients had higher values on the left side, while the remaining patient showed equal  $p_aCO_2$ -levels on both sides (Fig. 2). With variant 2, all patients ( $n = 7$ ) had higher  $p_aCO_2$  in the right radial artery compared to the postoxygenator ECMO circuit (Fig. 2). In five patients, in whom ABG samples were taken simultaneously from all three sites,  $p_aCO_2$ -level was higher in the left radial artery than in the postoxygenator ECMO circuit (median  $p_aCO_2$ -

**Table 1**


summarizes demographic data (sex, age), causes for VA-ECMO treatment, VA-ECMO flow rate, left ventricular ejection fraction (LVEF), cause of BD and mode of BD confirmation (type of ancillary test). Abbreviations used in the table are as follows: male (M), female (F), cardiopulmonary resuscitation (CPR), cardiogenic shock (CS), myocardial infarction (MI), pulmonary embolism (PE), ventricular fibrillation (VF), hypoxic encephalopathy (HE), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAE), perfusion scintigraphy (PS), somatosensory evoked potentials (SE), not assessed (n.a.).

Patient No.	Sex, age	Cause for VA-ECMO treatment	VA-ECMO flow rate	LVEF	Cause of BD	Ancillary test
1.	M, 51	CPR, asystolia, MI	3.5	10%	HE	EEG
2.	M, 39	CPR, PE	3.6	n.a.	HE	EEG
3.	M, 48	CPR, VF, MI	3.2	<5%	HE	EEG
4.	F, 76	CPR, VF, MI	3.5	n.a.	HE	EEG
5.	F, 38	CPR, PE	3.2	n.a.	HE	CT-angio
6.	M, 46	CPR, asystolia, MI	3.5	n.a.	HE	EEG
7.	M, 71	CPR, PE	3.8	<5%	HE	CT-Angio
8.	M, 46	CPR, asystolia	2.6	25%	HE	EEG
9.	M, 27	CPR, VF	3.8	<5%	HE	EEG, PS, TCD
10.	F, 32	CPR, drowning	4.5	n.a.	HE	EEG
11.	M, 52	CPR, MI	3.5	<5%	HE	EEG
12.	M, 48	CPR, MI	3.3	<5%	HE	EEG
13.	F, 34	CPR, VF	2.0	25%	HE	EEG
14.	M, 36	CPR, VF	2.5	35%	HE	EEG
15.	F, 75	CPR, cardiac arrest	3.6	n.a.	HE, ICH, SAH	EEG
16.	M, 58	CPR, PE	4.0	35%	HE	EEG
17.	M, 58	CPR, asystolia	2.6	n.a.	HE	EEG, SEP, PS
18.	M, 26	CPR, asystolia, drowning	3.4	15%	HE	EEG
19.	M, 56	CPR, VF	3.4	<5%	HE	EEG
20.	M, 49	CS, MI	4.7	10%	HE	EEG
21.	M, 44	CPR, MI	3.2	n.a.	HE	EEG
22.	M, 53	CPR, stunned myocardium	5.6	5%	SAH	EEG
23.	F, 36	CPR, PE	4.3	n.a.	HE	EEG
24.	M, 57	CPR, PE	3.5	60%	ICH, SAH	EEG
25.	M, 43	CPR, MI	n.a.	n.a.	HE, ICH	EEG
26.	F, 69	CS, MI	2.0	10%	HE	2nd clin. Exam
27.	F, 28	CPR, PE	3.5	n.a.	HE, ICH	EEG

difference 4.5 mmHg, range 0.1–7.2 mmHg). Here, median  $p_aCO_2$ -differences according to variant 1 and 2 were 1.0 and 3.4 mmHg (95%-CI: 0.1–2.8 and 0.3–7.8 mmHg).

#### 3.2. Simultaneous ABG analysis at the end of AT

At the end of AT,  $p_aCO_2$  of the right radial artery across all patients was 67.1 mmHg (IQR 64.8–72.4 mmHg, range 60.4–94.6 mmHg). With variant 1,  $p_aCO_2$ -levels in the right and left radial arteries were 66.6 and 68.2 mmHg (95%-CI: 66.3–72.5 and 66.8–72.8 mmHg;  $p = 0.81$ ). Fig. 2b illustrates the final distribution of all individual  $p_aCO_2$ -differences



**Fig. 2.** a–b. Distribution of individual  $p_aCO_2$ -differences as illustrated by points (variant 1) and circles (variant 2) for each patient. Points and circles on the left side of the x-axis represent patients in whom  $p_aCO_2$ -values were higher on the right radial artery as compared to either the left radial artery (variant 1) or the postoxygenator ECMO circuit (variant 2), and vice versa. Fig. 2 illustrates individual  $p_aCO_2$ -differences at the start of apnea testing ( $n = 25$  for variant 1 as illustrated by points;  $n = 7$  for variant 2 as illustrated by circles). Fig. 2b illustrates individual  $p_aCO_2$ -differences at the end of apnea testing.


according variant 1 and 2. The median  $p_aCO_2$ -difference for variant 1 was 1.1 mmHg (95%-CI: 0.9–1.8 mmHg, range 0.1–4.2 mmHg; Fig. 3). With regard to variant 2, final  $p_aCO_2$ -levels in the right radial artery and postoxygenator ECMO circuit were 74.8 and 60.9 mmHg (95%-CI: 64.1–84.1 and 59.7–65.8 mmHg;  $p = 0.04$ ). Here, the median  $p_aCO_2$ -difference was 9.9 mmHg (95%-CI: 3.5–19.2 mmHg, range 0.1–26.7 mmHg; Fig. 3), significantly higher than in variant 1 ( $p = 0.002$ ). Sixteen out of 25 patients in whom variant 1 was applied had slightly higher  $p_aCO_2$ -levels on the left as compared to the right side (Fig. 2b). In variant 2, again all patients ( $n = 7$ ) showed higher  $p_aCO_2$ -levels in the right radial artery compared to the postoxygenator ECMO (Fig. 2b). In five patients, in whom ABG samples were taken simultaneously from all three sites median  $p_aCO_2$ -difference between left radial artery and postoxygenator ECMO circuit was 11.4 mmHg (range 0.6–27.3 mmHg) and in each case  $p_aCO_2$  in the left radial artery was higher than in the postoxygenator ECMO circuit,  $p_aCO_2$ -differences according to variant 1 and 2 reached 1.8 and 14.7 mmHg (95%-CI: –2.3–14.0 and –0.4–25.1 mmHg).

Family members of nine patients agreed for organ donation, which was eventually realized in six cases (22.2% of all patients included in this).

#### 4. Discussion

In this study, we systematically analysed two different procedures addressing the Harlequin syndrome during AT in patients treated with VA-ECMO. As suggested by earlier reviews, the current 5th version of the German guideline advises simultaneous monitoring of  $p_aCO_2$  from distal arterial lines in both arms (variant 1) [8,9,17]. Authors from the recently published *American Brain Death/Death by Neurological Criteria Consensus Guideline 2023* and the *World Brain Death Project* propose taking simultaneous ABG samples from a right distal arterial line and from the postoxygenator ECMO circuit (variant 2) [16,20]. In our study, we systematically compared both variants, including their ability to ensure that specified  $p_aCO_2$ -thresholds are met during AT.

Simultaneous ABG sampling proved feasible to guide AT according to both variants. As the central finding, we demonstrate that  $p_aCO_2$  in the postoxygenator ECMO circuit does not closely reflect  $p_aCO_2$  in the left radial artery. We found a significant overestimation of the Harlequin effect by a factor of >3 already during normocapnic baseline ( $p_aCO_2$ -



**Fig. 3.** Comparison of  $p_aCO_2$ -differences as illustrated by box-plots with median, interquartile ranges and ranges according to variant 1 (grey box) and variant 2 (white box) at the start of apnea testing and end of apnea testing. At both time-points,  $p_aCO_2$ -differences according to variant 2 (simultaneous ABG samples from right radial artery and postoxygenator ECMO circuit) were significantly higher as compared to variant 1 (simultaneous ABG samples from right and left radial arteries).



differences of variant 1 vs. 2 were 0.90 vs. 3.3 mmHg;  $p = 0.001$ ). At the end of the AT, however, this factor increased to an average of 9 ( $p_aCO_2$ -differences of variant 1 vs. 2 were 1.1 vs. 9.9 mmHg;  $p = 0.002$ ). Here individual  $p_aCO_2$ -differences reached up to 26.7 mmHg. Similar results were reported in a series of three patients, with a  $p_aCO_2$ -difference between a right distal arterial line and the postoxygenator ECMO circuit of 9, 18, and 35 mmHg at the end of AT [21]. As a practical consequence, applying a  $p_aCO_2$ -threshold of 60 mmHg in the postoxygenator ECMO circuit may prolong the apneic phase by several minutes, thereby exposing the patient to an unnecessarily severe respiratory acidosis. In the mentioned example of our study, a  $p_aCO_2$  well above 85 mmHg was documented in the right radial artery when postoxygenator  $p_aCO_2$  reached 60 mmHg. Respiratory acidosis endangers the through an increased risk of cardiac arrhythmia and systemic hypotension.

AT requires demonstration of apnea when the  $p_aCO_2$  has increased above a defined threshold. The underlying assumption is that measured ABG values are representative of the  $p_aCO_2$ -level at the chemoreceptors of the medulla oblongata, which trigger spontaneous breathing. In patients on VA-ECMO, the concern is that antegrade and retrograde flow from the left ventricle and ECMO system, containing blood with different  $p_aCO_2$ -levels, may create an unpredictable mixing cloud in the aorta (Fig. 1). If located in the aortic arch, diverging  $p_aCO_2$ -levels in the right arm, medulla oblongata, left arm, and ECMO output may result. From a hypothetical point of view, the  $p_aCO_2$  in the mixing zone cannot be lower than the  $p_aCO_2$  minimum of the inputs. Thus, demonstrating above-threshold  $p_aCO_2$  in the postoxygenator ECMO circuit and in the right radial artery (variant 2) is a plausible approach to guarantee above-threshold  $p_aCO_2$  also in the medulla oblongata. However, if the mixing zone is located distal to the aortic arch,  $p_aCO_2$  in the left subclavian, vertebral and radial arteries will be closer to that in the right radial artery than in the ECMO output, meaning that  $p_aCO_2$  in the vertebral arteries and medulla oblongata should reach the target level earlier than  $p_aCO_2$  in the postmembrane ECMO circuit. As reflected by the difference in  $p_aCO_2$  between left radial artery and postoxygenator ECMO circuit, the mixing zone may often be located in the descending aorta. In our study, simultaneous ABG samples revealed a maximal  $p_aCO_2$ -difference of up to 27.3 mmHg between the left radial artery and the postoxygenator ECMO circuit at the end of AT. Based on vascular anatomy,  $p_aCO_2$  in the left vertebral artery should closely follow  $p_aCO_2$  in the left radial artery, regardless of the location of the mixing zone.

Independent of VA-ECMO, the safety of AT has been a matter of critical debate since the introduction of diagnostic protocols and guidelines for BD determination [23–25]. Systematic studies of cardiopulmonary parameters, cerebral hemodynamics, and invasive neuro-monitoring indicate that AT is safe if performed strictly according to guideline recommendations [26,27]. In ECMO-patients, a low to moderate complication rate of AT has been reported. A recent review summarized 17 case studies and case series ( $n = 67$ ) [6]. Here, AT was interrupted due to hemodynamic or respiratory instability in 9% of patients [21,28,29]. In our patients, results obtained with variant 1, variant 2, or both successfully guided AT without negative impact on cardiac, hemodynamic or respiratory stability. Interruption of AT was never required. To reach target  $p_aCO_2$  while on VA-ECMO, gas flow at the oxygenator membrane is reduced to decrease  $CO_2$  elimination. In patients with compromised alveolar diffusion, a high oxygen fraction may be required, limiting the achievable reduction in gas flow and  $CO_2$  washout. As a workaround, adding  $CO_2$  to the VA-ECMO gas mix has been reported in four patients [30]. Information regarding bilateral ABG sampling was not provided in the mentioned study. Based on the physiological considerations above, false-positive findings are unlikely with this method. In our study,  $CO_2$  supplementation was not necessary.

In view of its high inaccuracy and potential risks from excessive hypercapnia, we recommend against guiding AT by applying the  $p_aCO_2$ -threshold to the postoxygenator ECMO circuit. Instead, AT should be guided by  $p_aCO_2$  in distal arteries of the left and right arm, whenever possible. According to previous reports by the *Extracorporeal Life Support*

*Organization* providing data from different countries up to 7.9% of VA-ECMO patients developed BD [31]. In our study, only 1.8% of all patients treated with VA-ECMO were introduced for BD determination. This discrepancy may partly be explained by a decrease in the prevalence of acute brain injury during VA-ECMO treatment in recent years while the total number of VA-ECMO treatments has increased [32]. Another reason may be a persistent uncertainty on how to deal with challenging aspects of BD determination in patients with VA-ECMO. Our study aims to reduce this uncertainty by providing more evidence-based recommendations on how to perform the AT safely.

For future research, we recommend to continue simultaneous ABG sampling from both arms and the ECMO output to further investigate which ECMO-related parameters, echocardiography results or ABG constellations may predict the size of the  $p_aCO_2$ -differences during AT. These results could help identify situations in which a second arterial line may not be required.

#### 4.1. Limitations of the study

Although, our study might incorporate the highest number of patients included in a study to address the Harlequin syndrome in BD determination as by now, the overall number of patients is still low. Simultaneous  $p_aCO_2$  values from both right and left radial artery as well as postoxygenator blood gas were only available in five patients, hence majority of the data is describing interpatient comparisons. The retrospective design of our study does incorporate some methodological limitations. In fact, the retrospective design of our study, did not allow providing valid investigation of the time, which was needed to complete AT. Time between first and last ABG sampling does not necessarily reflect the actual times of the AT. Future studies should analyze “time of AT” as well as “pH-changes” prospectively.

The main objective of our study was to test the feasibility of simultaneous ABG sampling from both arms and/or the ECMO circuit to address the impact of a Harlequin syndrome. Objective visualization of the mixing cloud associated with the Harlequin syndrome itself was not part of our study. The manifestation of the Harlequin syndrome is dynamic and localization of the watershed may change across the aortic segments over time. CT-angiography may visualize the watershed across the aortic arch or the descending aorta. However, transportation of highly unstable ECMO-patients is hazardous, which was also a reason why CT-imaging was not performed in our patients for study purposes. For future studies, contrast-enhanced ultrasound might provide an easy-to-use bedside modality helping to identify patients at risk for a Harlequin syndrome.

## 5. Conclusions

Since further increase of ECLS utilization is expected, adequate knowledge about the specific challenges of BD determination in VA-ECMO patients is indispensable [4]. Based on our data, ABG samples taken simultaneously from right and left distal arterial lines should be the first choice in performing AT in VA-ECMO patients. If implantation of a second arterial line has failed, simultaneous ABG samples taken from the right radial artery and the postoxygenator ECMO circuit are an alternative that, however, may require more time for completion of AT.

## Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Authors' contributions

All authors contributed substantially to the conception and design of the study. Each author performed BD determination in patients included in this study and contributed to the acquisition of data. All authors

contributed substantially to the interpretation of the data. The first draft of the manuscript was written by the corresponding author F.S. and all authors commented on previous versions of the manuscript. All authors provided final approval of the version submitted for publication.

### CRedit authorship contribution statement

**Farid Salih:** Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Project administration, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. **Johann Lambeck:** Writing – review & editing, Validation, Methodology, Data curation. **Albrecht Günther:** Writing – review & editing, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. **Caroline Ferse:** Writing – review & editing, Methodology, Data curation, Conceptualization. **Olaf Hoffmann:** Writing – review & editing, Visualization, Methodology, Investigation, Data curation, Conceptualization. **Konstantinos Dimitriadis:** Writing – review & editing, Methodology, Investigation, Formal analysis, Data curation. **Andre Finn:** Writing – review & editing, Methodology, Investigation. **Stephan A. Brandt:** Writing – review & editing, Methodology, Investigation. **Benjamin Hotter:** Writing – review & editing, Methodology, Investigation. **Stephan Schreiber:** Writing – review & editing, Methodology, Investigation. **Florian Weissinger:** Writing – review & editing, Methodology, Investigation. **Andrea Rocco:** Writing – review & editing, Methodology, Investigation. **Hauke Schneider:** Writing – review & editing, Methodology, Investigation. **Wolf-Dirk Niesen:** Writing – review & editing, Supervision, Methodology, Investigation, Conceptualization.

### Declaration of competing interest

None.

### Data availability

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

### Acknowledgements

Not applicable.

### References

- [1] Lescoart M, Pequignot B, Janah D, Levy B. The medical treatment of cardiogenic shock. *J Intensive Med* 2023;3:114–23. <https://doi.org/10.1016/j.jointm.2022.12.001>.
- [2] Pollack BE, Kirsch R, Chapman R, Hyslop R, MacLaren G, Barbaro RP. Extracorporeal membrane oxygenation then and now; broadening indications and availability. *Crit Care Clin* 2023;39:255–75. <https://doi.org/10.1016/j.ccc.2022.09.003>.
- [3] Wieruszewski PM, Ortoleva JP, Cormican DS, Seelhammer TG. Extracorporeal membrane oxygenation in acute respiratory failure. *Pulm Ther* 2023;9:109–26. <https://doi.org/10.1007/s41030-023-00214-2>.
- [4] Bein T, Müller T, Citerio G. Determination of brain death under extracorporeal life support. *Intensive Care Med* 2019;45:364–6. <https://doi.org/10.1007/s00134-018-05510-z>.
- [5] Lie SA, Hwang NC. Challenges of brain death and apnea testing in adult patients on extracorporeal membrane oxygenation-a review. *J Cardiothorac Vasc Anesth* 2019; 33:2266–72. <https://doi.org/10.1053/j.jvca.2019.01.042>.
- [6] Sady ERR, Junqueira L, Veiga VC, Rojas SSO. Apnea test for brain death diagnosis in adults on extracorporeal membrane oxygenation: a review. *Rev Bras Ter Intensiva* 2020;32:312–8. <https://doi.org/10.5935/0103-507x.20200048>.
- [7] Migdady I, Stephens RS, Price C, et al. The use of apnea test and brain death determination in patients on extracorporeal membrane oxygenation: a systematic review. *J Thorac Cardiovasc Surg* 2021;162:867–877.e1.
- [8] Ihle J, Burrell A. Confirmation of brain death on VA-ECMO should mandate simultaneous distal arterial and post-oxygenator blood gas sampling. *Intensive Care Med* 2019;45:1165–6. <https://doi.org/10.1007/s00134-019-05637-7>.
- [9] Winter S, Groesdonk HV, Beiderlinden M. Apnea test for assessment of brain death under extracorporeal life support. *Med Klin Intensivmed Notfmed* 2019;114:15–20. German, <https://doi.org/10.1007/s00063-017-0287-8>.
- [10] Harrar DB, Kukreti V, Dean NP, Berger 3rd JT, Carpenter JL. Clinical determination of brain death in children supported by extracorporeal membrane oxygenation. *Neurocrit Care* 2019;31:304–11. <https://doi.org/10.1007/s12028-019-00700-z>.
- [11] Rao P, Khalpey Z, Smith R, Burkoff D, Kociol RDX. Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest. *Circ Heart Fail* 2018;11:e004905. <https://doi.org/10.1161/CIRCHEARTFAILURE.118.004905>.
- [12] Friedrichson B, Mutlak H, Zacharowski K, Piekarski F. Insight into ECMO, mortality and ARDS: a nationwide analysis of 45,647 ECMO runs. *Crit Care* 2021; 25:38. <https://doi.org/10.1186/s13054-021-03463-2>.
- [13] Karagiannidis C, Brodie D, Strassmann S, Stoelben E, Philipp A, Bein T, et al. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. *Intensive Care Med* 2016;42:889–96. <https://doi.org/10.1007/s00134-016-4273-z>.
- [14] Bronchard R, Durand L, Legeai C, Cohen J, Guerrini P, Bastien O. Brain-dead donors on extracorporeal membrane oxygenation. *Crit Care Med* 2017;45: 1734–41. <https://doi.org/10.1097/CCM.0000000000002564>.
- [15] Fainberg NA, Morrison WE, West S, Hasz R, Kirschen MP. Organ donation from patients on extracorporeal membrane oxygenation at the time of death. *Crit Care Explor* 2022;4:e0812. <https://doi.org/10.1097/CCE.0000000000000812>.
- [16] Greer DM, Kirschen MP, Lewis A, Gronseth GS, Rae-Grant A, Ashwal S, et al. Pediatric and adult brain death/death by neurologic criteria consensus guideline: report of the AAN guidelines subcommittee, AAP, CNS, and SCCM. *Neurology* 2023. <https://doi.org/10.1212/WNL.000000000000207740>.
- [17] Bundesärztekammer. Richtlinie gemäß § 16 Abs. 1 S. 1 Nr. 1 TPG für die Regeln zur Feststellung des Todes nach § 3 Abs. 1 S. 1 Nr. 2 TPG und die Verfahrensregeln zur Feststellung des endgültigen, nicht behebbaren Ausfalls der Gesamtfunktion des Großhirns, des Kleinhirns und des Hirnstamms nach § 3 Abs. 2 Nr. 2 TPG, Fünfte Fortschreibung. *Dtsch Arztebl.* 2022. [https://doi.org/10.3238/arztebl.2022.r1\\_hirnfunktionsausfall.02](https://doi.org/10.3238/arztebl.2022.r1_hirnfunktionsausfall.02).
- [18] Falk L, Sallissalmi M, Lindholm JA, Lindfors M, Frenckner B, Broomé M, et al. Differential hypoxemia during venoarterial extracorporeal membrane oxygenation. *Perfusion* 2019;34:22–9. <https://doi.org/10.1177/0267659119830513>.
- [19] Giunta M, Recchia EG, Capuano P, Toscano A, Attisani M, Rinaldi M, et al. Management of harlequin syndrome under ECPella support: a report of two cases and a proposed approach. *Ann Card Anaesth* 2023;26:97–101. <https://doi.org/10.4103/aca.aca.176.21>.
- [20] Greer DM, Shemie SD, Lewis A, Torrance S, Varelas P, Goldenberg FD, et al. Determination of brain death/death by neurologic criteria: the world brain death project. *JAMA* 2020;324:1078–97. <https://doi.org/10.1001/jama.2020.11586>.
- [21] Ihle JF, Burrell AJC, Philpot SJ, Pilcher DV, Murphy DA, Pellegrino VA. A protocol that mandates Postoxygenator and arterial blood gases to confirm brain death on Venoarterial extracorporeal membrane oxygenation. *ASAIO J* 2020;66:e23–8. <https://doi.org/10.1097/MAT.0000000000001086>.
- [22] Teasdale GM, Drake CG, Hunt W, Kassell N, Sano K, Pertuiset B, et al. A universal subarachnoid hemorrhage scale: report of a committee of the world federation of neurosurgical societies. *J Neurol Neurosurg Psychiatry* 1988;51:1457. <https://doi.org/10.1136/jnnp.51.11.1457>.
- [23] Tibballs J. A critique of the apneic oxygenation test for the diagnosis of “brain death”. *Pediatr Crit Care Med* 2010;11:475–8. <https://doi.org/10.1097/PCC.0b013e3181ce75dd>.
- [24] Lang CJ, Heckmann JG. Apnea testing for the diagnosis of brain death. *Acta Neurol Scand* 2005;112:358–69. <https://doi.org/10.1111/j.1600-0404.2005.00527.x>.
- [25] Joffe AR, Anton NR, Duff JP. The apnea test: rationale, confounders, and criticism. *J Child Neurol* 2010;25:1435–43. <https://doi.org/10.1177/0883073810369380>.
- [26] Salih F, Hoffmann O, Brandt SA, Masuhr F, Schreiber S, Weissinger F, et al. Safety of apnea testing for the diagnosis of brain death: a comprehensive study on neuromonitoring data and blood gas analysis. *Eur J Neurol* 2019;26:887–92. <https://doi.org/10.1111/ene.13903>.
- [27] Datar S, Fugate J, Rabinstein A, Couillard P, Wijidicks EF. Completing the apnea test: decline in complications. *Neurocrit Care* 2014;21:392–6. <https://doi.org/10.1007/s12028-014-9958-y>.
- [28] Giani M, Scaravilli V, Colombo SM, Confalonieri A, Leo R, Maggioni E, et al. Apnea test during brain death assessment in mechanically ventilated and ECMO patients. *Intensive Care Med* 2016;42:72–81. <https://doi.org/10.1007/s00134-015-4105-6>.
- [29] Champigneulle B, Chhor V, Mantz J, Journois D. Efficiency and safety of apnea test process under extracorporeal membrane oxygenation: the most effective method remains questionable. *Intensive Care Med* 2016;42:1098–9. <https://doi.org/10.1007/s00134-016-4265-z>.
- [30] Zhao DX, Caturegli G, Wilcox C, Stephens RS, Kim BS, Keller S, et al. Challenges in determining death by neurologic criteria in extracorporeal membrane oxygenation - a single center experience. *Perfusion* 2023;30. <https://doi.org/10.1177/02676591231187548>. 2676591231187548.
- [31] Lorusso R, Barili F, Mauro MD, Gelsomino S, Parise O, Rycus PT, et al. In-hospital neurologic complications in adult patients undergoing Venoarterial extracorporeal membrane oxygenation: results from the extracorporeal life support organization registry. *Crit Care Med* 2016;44:e964–72. <https://doi.org/10.1097/CCM.0000000000001865>.
- [32] Cho SM, Canner J, Chiarini G, Calligy K, Caturegli G, Rycus P, et al. Modifiable risk factors and mortality from ischemic and hemorrhagic strokes in patients receiving Venoarterial extracorporeal membrane oxygenation: results from the extracorporeal life support organization registry. *Crit Care Med* 2020;48: e897–905. <https://doi.org/10.1097/CCM.0000000000004498>.